Administration and Dosing of Systemic Antifungal Agents in Pediatric Patients.

TitleAdministration and Dosing of Systemic Antifungal Agents in Pediatric Patients.
Publication TypeJournal Article
Year of Publication2020
AuthorsDownes KJ, Fisher BT, Zane NR
JournalPaediatr Drugs
Date Published2020 Jan 23
ISSN1179-2019
Abstract

Neonates and immunosuppressed/immunocompromised pediatric patients are at high risk of invasive fungal diseases. Appropriate antifungal selection and optimized dosing are imperative to the successful prevention and treatment of these life-threatening infections. Conventional amphotericin B was the mainstay of antifungal therapy for many decades, but dose-limiting nephrotoxicity and infusion-related adverse events impeded its use. Despite the development of several new antifungal classes and agents in the past 20 years, and their now routine use in at-risk pediatric populations, data to guide the optimal dosing of antifungals in children are limited. This paper reviews the spectra of activity for approved antifungal agents and summarizes the current literature specific to pediatric patients regarding pharmacokinetic/pharmacodynamic data, dosing, and therapeutic drug monitoring.

DOI10.1007/s40272-020-00379-2
Alternate JournalPaediatr Drugs
PubMed ID31974859
Grant ListK23HD091365 / / Eunice Kennedy Shriver National Institute of Child Health and Human Development /
1K99HD096123 / / Eunice Kennedy Shriver National Institute of Child Health and Human Development /